About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New US Regulation Creates Fresh Challenges for Indian Drugmaker Ranbaxy

by Savitha C Muppala on September 16, 2013 at 11:30 PM
Font : A-A+

 New US Regulation Creates Fresh Challenges for Indian Drugmaker Ranbaxy

Shares in Indian generic drugs giant Ranbaxy Laboratories crashed as much as 35 percent in early trade on Monday after the US Food and Drug Administration suspended imports from one of its factories.

Ranbaxy slid to 297.25 rupees on the Bombay Stock Exchange, down 34.99 percent, before recovering to 341.00 rupees, down 25.42 percent.

Advertisement

The FDA issued an alert on Friday against a Ranbaxy factory in Mohali in the northern state of Punjab, meaning imports are suspended from the plant.

A spokesman for Ranbaxy, part of Japan's Daiichi Sankyo group, was not immediately available for comment.

In May, Ranbaxy pleaded guilty to US charges of selling adulterated antibiotic, acne, epilepsy and other drugs and agreed to a record $500-million fine.
Advertisement

The US fraud, uncovered over eight years, was exposed by a whistle-blowing ex-employee who said Ranbaxy created "a complicated trail of falsified records and dangerous manufacturing practices".

India's drug industry has come under scrutiny from global regulators in recent months over suspected manufacturing problems at factories.

In July Britain's healthcare regulator recalled 16 drugs from Indian pharmaceutical firm Wockhardt after finding deficiencies at one of its local manufacturing plants.

India's government has defended its lucrative generic drug industry, which accounts for nearly $15 billion in annual exports, as safe and tightly regulated.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Link between Dietary Intake of Plant-based Essential Fatty Acids and Death Risk
Aspirin may be Harmful When Used for Preventing 1st Heart Attack, Stroke
Pregnancy Complications Elevated Among Symptomatic COVID-19 Women
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.


Recommended Reading
US Authorities Fines Indian Generic Drug Giant Ranbaxy $500 Mn
A $500 million dollar fine was announced by US authorities against Indian generic pharmaceutical ......
Ranbaxy Halts Production of Generic Lipitor to Investigate Glass Particle Contamination of Drug
Indian pharmaceutical company Ranbaxy Laboratories confirmed that it will be stopping the ......
New Generic Anti-depressant to be Introduced by Ranbaxy
Ranbaxy jumps into an in-licensing agreement with Alembic Pharmaceuticals to start marketing the ......

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use